This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by García-Garrote, F.
Right arrow Articles by Bouza, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by García-Garrote, F.
Right arrow Articles by Bouza, E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 1998, p. 2452-2455, Vol. 42, No. 9
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

In Vitro Activity of the New Glycopeptide LY333328 against Multiply Resistant Gram-Positive Clinical Isolates

Fernando García-Garrote,* Emilia Cercenado, Luis Alcalá, and Emilio Bouza

Servicio de Microbiología, Hospital General Universitario "Gregorio Marañón," Madrid, Spain

Received 27 January 1998/Returned for modification 22 April 1998/Accepted 29 June 1998

The in vitro activity of LY333328 was compared with those of vancomycin and teicoplanin against 425 gram-positive clinical isolates, including a variety of multiply resistant strains. LY333328 at <= 4 µg/ml inhibited all microorganisms tested, including methicillin- and teicoplanin-resistant staphylococci, glycopeptide-resistant enterococci, penicillin- and multiply resistant pneumococci, and viridans and beta-hemolytic streptococci.

* Corresponding author. Mailing address: Servicio de Microbiología, Hospital General Universitario "Gregorio Marañón," Dr. Esquerdo 46, 28007 Madrid, Spain. Phone: (341) 586-8453. Fax: (341) 504-4906. E-mail: fgarrote{at}efd.net.

Antimicrobial Agents and Chemotherapy, September 1998, p. 2452-2455, Vol. 42, No. 9
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Arhin, F. F., Sarmiento, I., Belley, A., McKay, G. A., Draghi, D. C., Grover, P., Sahm, D. F., Parr, T. R. Jr., Moeck, G. (2008). Effect of Polysorbate 80 on Oritavancin Binding to Plastic Surfaces: Implications for Susceptibility Testing. Antimicrob. Agents Chemother. 52: 1597-1603 [Abstract] [Full Text]  
  • Attwood, R. J., LaPlante, K. L. (2007). Telavancin: A novel lipoglycopeptide antimicrobial agent. Am J Health Syst Pharm 64: 2335-2348 [Abstract] [Full Text]  
  • Petersen, P. J., Wang, T. Z., Dushin, R. G., Bradford, P. A. (2004). Comparative In Vitro Activities of AC98-6446, a Novel Semisynthetic Glycopeptide Derivative of the Natural Product Mannopeptimycin {alpha}, and Other Antimicrobial Agents against Gram-Positive Clinical Isolates. Antimicrob. Agents Chemother. 48: 739-746 [Abstract] [Full Text]  
  • Cabellos, C., Fernandez, A., Maiques, J. M., Tubau, F., Ardanuy, C., Viladrich, P. F., Linares, J., Gudiol, F. (2003). Experimental Study of LY333328 (Oritavancin), Alone and in Combination, in Therapy of Cephalosporin-Resistant Pneumococcal Meningitis. Antimicrob. Agents Chemother. 47: 1907-1911 [Abstract] [Full Text]  
  • Petersen, P. J., Bradford, P. A., Weiss, W. J., Murphy, T. M., Sum, P. E., Projan, S. J. (2002). In Vitro and In Vivo Activities of Tigecycline (GAR-936), Daptomycin, and Comparative Antimicrobial Agents against Glycopeptide-Intermediate Staphylococcus aureus and Other Resistant Gram-Positive Pathogens. Antimicrob. Agents Chemother. 46: 2595-2601 [Abstract] [Full Text]  
  • Noviello, S., Ianniello, F., Esposito, S. (2001). In vitro activity of LY333328 (oritavancin) against Gram-positive aerobic cocci and synergy with ciprofloxacin against enterococci. J Antimicrob Chemother 48: 283-286 [Abstract] [Full Text]  
  • Gerber, J., Smirnov, A., Wellmer, A., Ragheb, J., Prange, J., Schutz, E., Wettich, K., Kalich, S., Nau, R. (2001). Activity of LY333328 in Experimental Meningitis Caused by a Streptococcus pneumoniae Strain Susceptible to Penicillin. Antimicrob. Agents Chemother. 45: 2169-2172 [Abstract] [Full Text]  
  • Coyle, E. A., Rybak, M. J. (2001). Activity of Oritavancin (LY333328), an Investigational Glycopeptide, Compared to That of Vancomycin against Multidrug-Resistant Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model. Antimicrob. Agents Chemother. 45: 706-709 [Abstract] [Full Text]  
  • Zeckel, M. L., Preston, D. A., Allen, B. S. (2000). In Vitro Activities of LY333328 and Comparative Agents against Nosocomial Gram-Positive Pathogens Collected in a 1997 Global Surveillance Study. Antimicrob. Agents Chemother. 44: 1370-1374 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»